Article Versions Notes

Almangour TA, Alkherb Z, Ghonem L, Al Musawa M, Almohaizeie A, Almuhisen S, Alharbi A, Damfu N, Aljefri D, Alghaith J, et al. Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Cohort Study. Pharmaceuticals. 2025; 18(1):108. https://doi.org/10.3390/ph18010108

Almangour, Thamer A., Zakiyah Alkherb, Leen Ghonem, Mohammed Al Musawa, Abdullah Almohaizeie, Sara Almuhisen, Aminah Alharbi, Nader Damfu, Doaa Aljefri, Jeelan Alghaith, and et al. 2025. "Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Cohort Study" Pharmaceuticals 18, no. 1: 108. https://doi.org/10.3390/ph18010108

Almangour, T. A., Alkherb, Z., Ghonem, L., Al Musawa, M., Almohaizeie, A., Almuhisen, S., Alharbi, A., Damfu, N., Aljefri, D., Alghaith, J., Alfozan, A., Alghamdi, A., Aljabri, A., Alhifany, A. A., Alessa, M., & Alsowaida, Y. S. (2025). Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Cohort Study. Pharmaceuticals, 18(1), 108. https://doi.org/10.3390/ph18010108